. Author manuscript; available in PMC: 2020 Mar 26.

Published in final edited form as: J Clin Immunol. 2019 Mar 26;39(2):216–224. doi: 10.1007/s10875-019-00613-8

Table 1:

Subject Characteristics

	PCD (n=27)	PID (n=32)

Median age in years (IQR)	18.6 (9.7–38.6)	16.5 (9.8–45.3)
Male sex (%)	12 (44)	17 (53)
White race (%)	18 (67)	26 (81)
Median FEV₁ % predicted (IQR)	81 (59–91)	94.1 (87–101)^*
Median FVC % predicted (IQR)	92 (80–99)	97 (87–106)
Median FEV₁/FVC % predicted (IQR)	88 (83–89)	87 (83–90)
Treatment nasal CS (%)	17 (63)	17 (53)
Treatment nasal saline lavage (%)	13 (48)	0 (0)^*
Previous FESS (%)	12 (44)	4 (13)^*
Past nasal polyps (%)	6 (22)	0^*
Prophylactic oral antibiotics (%)^†	8 (30)	12 (38)
Prophylactic inhaled antibiotics (%)^‡	2 (7)	0
IVIG replacement (%)	0	23 (72)^*
Current smoker (%)	0	6 (19)^*
Smoker in the home (%)	0	7 (22)^*

PID = primary immunodeficiency disease; PCD = primary ciliary dyskinesia; FEV₁ = Forced expiratory volume in 1 second, FVC= forced vital capacity; CS = corticosteroid; IVIG = intravenous immunoglobulin

Statistically significant values using Fisher Exact Test

^†

includes azithromycin, moxifloxacin, ciprofloxacin, TMP-SMX, amoxicillin

^‡

includes inhaled tobramycin